REG - Triton Inv Advsr LLP - Announcement made following a related announcement

Spire HealthcareAnnouncement

20/03/2026 17:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260320:nRST5455Xa&default-theme=true

RNS Number : 5455X  Triton Investments Advisers LLP  20 March 2026

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR
FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS
AND MERGERS (THE "CODE")

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

FOR IMMEDIATE RELEASE

 20 March 2026

Triton Investments Advisers LLP ("Triton")

No intention to make an offer for Spire Healthcare Group plc ("Spire
Healthcare" or the "Company")

Further to the announcement made by Spire Healthcare on 18 February 2026
regarding the discussions between Triton and the Company in the context of the
strategic review announced by Spire Healthcare on 18 September 2025, Triton
confirms that it does not intend to make a firm offer for Spire Healthcare.

This is a statement to which Rule 2.8 of the Code applies. Accordingly, Triton
and any person(s) acting in concert with it will, except with the consent of
the Panel on Takeovers and Mergers (the "Takeover Panel"), be bound by the
restrictions set out in Rule 2.8 of the Code.

Under Note 2 on Rule 2.8 of the Code, Triton, and any person(s) acting in
concert with it, reserve the right to set the restrictions in Rule 2.8 aside
in the following circumstances:

(a)      with the agreement of the board of directors of Spire
Healthcare;

(b)      following the announcement of a firm intention to make an offer
for Spire Healthcare by, or on behalf of, a third party, including Bridgepoint
Advisers Limited;

(c)      following the announcement by Spire Healthcare of a Rule 9
waiver proposal (see Note 1 of the Notes on Dispensations from Rule 9 of the
Code) or a reverse takeover (as defined in the Code); or

(d)      if there has been a material change of circumstances (as
determined by the Takeover Panel).

Important notices

This announcement is not intended to, and does not, constitute or form part of
any offer, invitation or the solicitation of an offer to purchase, otherwise
acquire, subscribe for, sell or otherwise dispose of, any securities, or the
solicitation of any vote or approval in any jurisdiction, pursuant to this
announcement or otherwise.

The distribution of this announcement in jurisdictions other than the United
Kingdom may be affected by the laws of relevant jurisdictions. Therefore, any
persons who are subject to the laws of any jurisdiction other than the United
Kingdom or shareholders of Spire Healthcare who are not resident in the United
Kingdom will need to inform themselves about, and observe, any applicable
requirements.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FURJMMFTMTTTBRF



            Copyright 2019 Regulatory News Service, all rights reserved